STAGES OF ONCOLOGY DEVELOPMENT AND CURRENT STATE IN GEORGIA
DOI:
https://doi.org/10.52340/jecm.2026.03.01Keywords:
oncology, cancer, registry, incidence, survival, screening, GeorgiaAbstract
Background: Cancer remains one of the major public health challenges in Georgia. During recent decades, substantial progress has occurred in cancer registration, diagnosis, screening and treatment. The establishment of a population-based national cancer registry on 1 January 2015 was a major milestone in the development of oncology in Georgia.
Objective: to summarize the major historical stages of oncology development in Georgia and assess the current epidemiological situation, diagnostic and therapeutic capacity, and major challenges of the national oncology system.
Materials and Methods: A focused review of scientific literature and official national and international sources was conducted. PubMed/MEDLINE, the International Agency for Research on Cancer Global Cancer Observatory, Georgian cancer registry data and official health-sector information were considered. Particular attention was given to studies published after 2015.
Results: Oncology in Georgia initially developed around surgical and radiation treatment and subsequently evolved toward a multidisciplinary model. According to national cancer registry data, 50,098 cancer cases were registered in Georgia between 2015 and 2019, including 21,802 cases in men and 28,296 in women. Lung, prostate, bladder and colorectal cancers were among the most common cancers in men, while breast, thyroid, colorectal, cervical and corpus uteri cancers predominated among women. Population-based data showed three-year age-standardized net survival of 84.4% for breast cancer and 30.6% for stomach cancer. Access to chemotherapy, radiotherapy, immunotherapy and targeted treatment has expanded substantially in recent years.
Conclusion: Georgian oncology has undergone considerable modernization. Future progress should focus on earlier diagnosis, improved screening participation, development of molecular diagnostics and precision oncology, reduction of regional inequalities, and strengthening of patient-centered supportive and palliative care.
Downloads
References
1. World Health Organization. Cancer. Geneva: World Health Organization; 2024.
2. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249. doi:10.3322/caac.21660.
3. Beraia A, Znaor A, Anda EE, Gamkrelidze A, et al. Incidence of common cancers in Georgia in 2015–2019: a national cancer registry study. Cancer Treat Res Commun. 2026;48:101267. doi:10.1016/j.ctarc.2026.101267.
4. Matz M, Gamkrelidze A, Mebonia N, Kereselidze M, Kazanjan K, Zhizhilashvili S, Atun R, Coleman MP, Allemani C. Survival from five common cancers in Georgia, 2015–2019 (CONCORD). Cancer Epidemiol. 2022;79:102190. doi:10.1016/j.canep.2022.102190.
5. World Health Organization. Guide to Cancer Early Diagnosis. Geneva: World Health Organization; 2017.
6. International Agency for Research on Cancer. Global Cancer Observatory: Cancer Today. Lyon: International Agency for Research on Cancer; 2024.
7. Havel JJ, Chowell D, Chan TA. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer. 2019;19:133-150. doi:10.1038/s41568-019-0116-x.
8. Ribas A, Wolchok JD. Science of melanoma immunotherapy: state of the art and future directions. Science. 2018;359(6375):1350-1355. doi:10.1126/science.aar4060.
9. World Health Organization. Integrating Palliative Care and Symptom Relief into Primary Health Care. Geneva: World Health Organization; 2018.
10. Staff NP, Grisold A, Grisold W, Windebank AJ. Chemotherapy-induced peripheral neuropathy: a current review. Ann Neurol. 2017;81(6):772-781. doi:10.1002/ana.24951.
11. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singap. 1994;23(2):129-138.
12. Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nikšić M, et al. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391(10125):1023-1075. doi:10.1016/S0140-6736(17)33326-3.
13. Allemani C, Weir HK, Carreira H, Harewood R, Spika D, Wang XS, et al. Global surveillance of cancer survival 1995–2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries. Lancet. 2015;385(9972):977-1010. doi:10.1016/S0140-6736(14)62038-9.
14. Coleman MP. Cancer survival: global surveillance will stimulate health policy and improve equity. Lancet. 2014;383(9915):564-573. doi:10.1016/S0140-6736(13)62225-4.
15. World Health Organization. WHO Report on Cancer: Setting Priorities, Investing Wisely and Providing Care for All. Geneva: World Health Organization; 2020.
16. International Agency for Research on Cancer. Cancer Screening in Five Continents (CanScreen5). Lyon: IARC; 2023.
17. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-263.
18. World Health Organization Regional Office for Europe. Cancer screening and early detection of cancer. Copenhagen: WHO Regional Office for Europe.
19. Cleeland CS. The impact of pain on the patient with cancer. Cancer. 1984;54(11 Suppl):2635-2641.
20. Seretny M, Currie GL, Sena ES, Ramnarine S, Grant R, MacLeod MR, et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain. 2014;155(12):2461-2470. doi:10.1016/j.pain.2014.09.020.
21. Jordan B, Margulies A, Cardoso F, Cavaletti G, Haugnes HS, Jahn P, et al. Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO-EONS-EANO Clinical Practice Guideline. Ann Oncol. 2020;31(10):1306-1319. doi:10.1016/j.annonc.2020.07.003.
22. National Center for Disease Control and Public Health, Georgia. Cancer Registry and cancer epidemiology data. Tbilisi: NCDC; 2024.
23. Ministry of Internally Displaced Persons from the Occupied Territories, Labour, Health and Social Affairs of Georgia. National cancer control and oncology care programme data. Tbilisi; 2024.
Downloads
Published
How to Cite
Issue
Section
